Nonapeptide-1 vs Prostamax
Side-by-side comparison of key properties, dosing, and research.
Skin & Cosmetic
Nonapeptide-1Anti-Aging & Longevity
Prostamax- Summary
- Nonapeptide-1 is a synthetic 9-amino acid peptide that inhibits melanin production by blocking α-MSH (alpha-melanocyte stimulating hormone) receptor binding. Used in cosmetic formulations for skin lightening and evening skin tone, it is particularly effective for UV-induced and hormonal hyperpigmentation.
- Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
- Half-Life
- Not applicable (topical)
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- Topical
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 0.05–0.5% concentration in formulation
- 10 mg per day
- Frequency
- Twice daily
- Daily for 10–30 days
- Key Benefits
- Inhibits UV-induced tanning and hyperpigmentation
- Reduces hormonal melasma
- Evens skin tone at receptor level
- Well-tolerated with minimal irritation
- Complementary to tyrosinase inhibitors for enhanced brightening
- Reduces post-inflammatory hyperpigmentation
- Supports normalization of prostate tissue architecture
- May reduce prostate enlargement associated with BPH
- Anti-inflammatory effects on prostatic tissue
- Reduces prostate cell apoptosis from oxidative stress
- Potential support in chronic prostatitis
- Anti-aging effects on prostate glandular tissue
- Complementary to conventional BPH therapies
- Side Effects
- Generally very well-tolerated
- Rare contact sensitivity in susceptible individuals
- Theoretical risk of excessive depigmentation with prolonged high-concentration use
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse urological events reported at standard doses
- Stacks With
- —
- —